| Next 10 |
Ad
SILO News and Press Silo Pharma Inc.
News | Silo Pharma Inc. (NASDAQ:SILO)
-
Silo Pharma (NASDAQ: SILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibili...
-
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on dev...
-
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE...
-
Silo Pharma (NASDAQ: SILO) , a biopharmaceutical company developing innovative treatments, announced promising results from recent tests on its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. Conducted with Sever Pharma Solutions, the sterilization and dissolution tests showed a ...
-
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutic...
-
2024-09-10 10:31:14 ET Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has completed a pre-Investigational New Drug (“IND&#...
-
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has completed a pre-Investigational New Drug (“IND”) meeting with the U.S. Food an...
-
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev...
-
2024-08-21 17:52:13 ET More on Silo Pharma Silo Pharma announces partnership with global CRO for central nervous system homing peptide Silo Pharma stock plummets on $2.1M registered direct offering priced ATM Financial information for Silo Pharma Read the f...
-
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered a new agreement with Sever Pharma Solutions. According to the announcement, the agre...
Stock Information
Get SILO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Silo Pharma (NASDAQ: SILO) has entered into a collaboration with Kymanox to develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant designed to treat fibromyalgia and chronic pain. The partnership will begin with proof-of-concept design, followed by prototype and feasibili...
-
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on dev...
-
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE...